PRAME antibody (C-Term)

Catalog No. ABIN5540467

This anti-PRAME antibody is a Rabbit Polyclonal antibody detecting PRAME in WB and ELISA (Detection). Suitable for Human.

Quick Overview for PRAME antibody (C-Term) (ABIN5540467)

Target: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This PRAME antibody is un-conjugated

Application: Western Blotting (WB), ELISA (Detection)

Product Details anti-PRAME Antibody

Binding Specificity: AA 321-509, C-Term

Specificity: This antibody detects PRAME / MAPE at C-term.

Purification: Protein A chromatography

Immunogen: Highly pure (> 95%) recombinant human PAME /MAPE C-terminal end (Met321-Asn509) derived from E. coli

Isotype: IgG

Application Details

Application Notes: Western blot: 1-5 μg/mL. ELISA: 0.1-1 μg/mL.

Restrictions: For Research Use only

Handling

Buffer: PBS

Storage: 4 °C,-20 °C

Storage Comment: Store lyophilized at 2-8°C for 6 month or at -20°C long term. After reconstitution store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C long term. Avoid repeated freezing and thawing. Shelf life: one year from despatch.

Expiry Date: 12 months

Target Details for PRAME

Target: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Alternative Name: prame,mape

Background: PRAME/MAPE/OIP4 is a germinal tissue-specific gene that is also expressed at high levels in haematological malignancies and solid tumors. The physiological functions of PRAME in normal and tumor cells are unknown, although a role in the regulation of retinoic acid signaling has been proposed. Sequence homology and structural predictions suggest that PRAME is related to the Leucine-rich repeat (LRR) family of proteins, which have diverse functions. PRAME, or "preferentially expressed antigen in melanoma", was originally identified as a gene encoding a HLA-A24 restricted antigenic peptide presented to autologous tumor-specific cytotoxic T lymphocytes derived from a patient with melanoma. PRAME is synonymous with MAPE (melanoma antigen preferentially expressed in tumors) and OIP4 (OPA-interacting protein 4), and its expression profile defines it as a cancer-testis antigen. Cancer-testis antigens (CTAs) are encoded by non-mutated genes expressed at high levels in germinal tissues and tumors, but which are absent from or detected at low levels in other tissues. PRAME may be somewhat different to other cancer-testis antigens in that it shows some expression in normal tissues such as ovary, adrenal, placenta and endometrium. The C-terminus of human PRAME (amino acids 453-509) was also identified to bind Neisseria gonorrhoeae opacity factors, in this case the OPA-P protein. Thus PRAME is also known as OIP4 (OPA interacting protein).

Pathways: Retinoic Acid Receptor Signaling Pathway, Nuclear Hormone Receptor Binding